Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) currently holds a neutral rating as per Andres Y. Maldonado of HC Wainwright & Co., reflecting a cautious outlook for investors amid recent fluctuations in stock performance. With the company’s shares priced at $21.33 and a price target of $22, the potential for moderate upside aligns with its recent trading patterns, providing both opportunities and challenges for interested investors.
Recent Price Action
In the last several trading sessions, Day One Biopharmaceuticals has experienced notable price movements, closing at $21.33. This figure contrasts sharply with its 52-week high of $19.32 and a staggering low of $89, suggesting considerable volatility. The stock has seen a slight increase, with a change of 0.0095, translating to a modest gain of approximately 0.04%. On average, approximately 2.27 million shares have traded, falling short of its average volume of 3.91 million, which hints at fluctuating investor enthusiasm. Compounding the stock’s daily trading behavior, its beta of -1.251 may signal a potential inverse relationship with the broader market, underlining a unique risk profile for prospective investors.
Short- and Long-Term Performance
In assessing Day One Biopharmaceuticals’ performance, the past month has showcased a remarkable 38.24% increase, while the quarterly returns are even more impressive at 68.19%. However, the yearly performance tells a different story, revealing a decline of 2.34%. The stock’s recent activity has illustrated notable weekly volatility of 11.83%, compounded by monthly volatility of 7.99%. As such, while short- and medium-term trends appear robust, the overall annual trajectory raises questions about sustainability. Over the past three months, the stock has averaged 23.39 million shares traded daily, pushing the narrative of rapid changes in investor sentiment and market engagement.
Earnings / Financials
On November 4, 2025, Day One Biopharmaceuticals reported an earnings per share (EPS) of -$0.19, which fell favorably against the estimated EPS of -$0.27839. This translates to a surprise factor of 31.75%, indicating an unexpected degree of financial resilience in a challenging market environment. In its previous earnings report from August 5, 2025, the company had an EPS of -$0.29, which also surpassed the estimate of -$0.35, suggesting a trend of better-than-expected fiscal results. However, despite these positive surprises, the overall EPS numbers still remain negative, which could deter risk-averse investors.
Analyst / Consensus View
The latest consensus from analysts covering Day One Biopharmaceuticals yields a mixed sentiment. HC Wainwright & Co. has adjusted its rating to Neutral as of March 10, 2026, while the average price target stands at approximately $25.79. Interestingly, the target range presents a high of $34 and a low of $18. Currently, there are seven total ratings, which include four “Buy” and three “Hold,” with no “Sell” recommendations. This collective sentiment suggests that while some analysts recognize potential growth prospects for DAWN, others remain cautious, advocating for a more measured approach to investment in the stock.
Stock Grading or Fundamental View
Day One Biopharmaceuticals, Inc. holds a Stocks Telegraph Grade (ST Score) of 52, a score that incorporates various indicators of the company’s financial and operational health. This score reflects a moderate investment profile. While the company exhibits some solid fundamentals, including the recent earnings surprises, its ongoing challenges in terms of revenue growth and stock volatility underscore the necessity for critical evaluation prior to investment.
Conclusion
For investors contemplating exposure to Day One Biopharmaceuticals, a careful assessment is warranted. The stock may appeal to growth-oriented investors willing to embrace moderate risk, given its impressive short- and medium-term performance alongside a favorable earnings surprise. Nonetheless, the historical volatility and negative overall trajectory raise legitimate concerns about the sustainability of these gains. Therefore, while DAWN presents an intriguing narrative within the burgeoning biopharmaceutical sector, investors should remain vigilant regarding external market conditions and inherent business risks as they decide the appropriateness of this stock in their portfolios.